<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015101024459N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-01-14</date_registration>
      <primary_sponsor>Farabi Eye Hospital</primary_sponsor>
      <public_title>Effect of mitomycin C in glaucoma shunt surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation the Efficacy of Ahmed Glaucoma Valve Implantation with and with out Mitomycin C(MMC) during surgery in patients with glaucoma</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/20639</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>glaucoma.</hc_freetext>
      <i_freetext>Intervention 1: After informing the patients about the procedure, and signing a consent form, the patients were randomly divided in two groups to receive intra-operative MMC or a Placebo. The surgical procedure consisted of a 1-stage Ahmed Glaucoma Valve implantation using a standardized surgical technique for all patients.  After administration of topical anesthesia (in both groups), a fornix or limbal based cojunctival flap was applied in the superotemporal quadrant. For the control group, a cotton applicator soaked in a balanced salt solution (BSS) was placed on the Episclera, under the conjunctiva and Tenon’s capsule for a contact time of 2 minutes ,at the site where the implant plate was to be placed, followed by irrigation with 30 ml of BSS. Then the tube was positioned in the anterior chamber or the sulcus. A donor sclera or a corneal lenticule was fashioned from banked tissue and secured with interrupted 8-0 vicryl sutures over the exposed portion of the tube. Intervention 2: After informing the patients about the procedure, and signing a consent form, the patients were randomly divided in two groups to receive intra-operative MMC or a Placebo. The surgical procedure consisted of a 1-stage Ahmed Glaucoma Valve implantation using a standardized surgical technique for all patients. After administration of topical anesthesia (in both groups), a fornix or limbal based cojunctival flap was applied in the superotemporal quadrant. For the intervention group, a cotton applicator soaked in a balanced salt solution (BSS) was placed on the Episclera, under the conjunctiva and Tenon’s capsule for a contact time of 2 minutes ,at the site where the implant plate was to be placed, followed by irrigation with 30 ml of BSS. Then the tube was positioned in the anterior chamber or the sulcus. A donor sclera or a corneal lenticule was fashioned from banked tissue and secured with interrupted 8-0 vicryl sutures over the exposed portion of the tube.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Doctor Ghasem Fakhraee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 13366, Farab eye Hospital, Qazvin square, South Kargar Avenue, Tehraan</address>
        <city>Tehraan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 215540000314</telephone>
        <email>drfakhraee@yahoo.com</email>
        <affiliation>Farabi Eye Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Doctor Ghasem Fakhraee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.13366, Farab ieye Hospital, Qazvin square, South Kargar Avenue, Tehraan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 215540000314</telephone>
        <email>drfakhraee@yahoo.com</email>
        <affiliation>Farabi Eye Hosppital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>inclusion criteria:Uncontrolled glaucoma patients under 18 years that are candidates for shunt surgery&#13;
exclusion criteria:Patients under 18 years; active iris neovascularization; anterior staphyloma; Breast-feeding and pregnancy; Previous shunt surgery; corneal lesions Which prevents IOP measurement</inclusion_criteria>
      <agemin>17 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Glaucoma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>After informing the patients about the procedure, and signing a consent form, the patients were randomly divided in two groups to receive intra-operative MMC or a Placebo. The surgical procedure consisted of a 1-stage Ahmed Glaucoma Valve implantation using a standardized surgical technique for all patients.  After administration of topical anesthesia (in both groups), a fornix or limbal based cojunctival flap was applied in the superotemporal quadrant. For the control group, a cotton applicator soaked in a balanced salt solution (BSS) was placed on the Episclera, under the conjunctiva and Tenon’s capsule for a contact time of 2 minutes ,at the site where the implant plate was to be placed, followed by irrigation with 30 ml of BSS. Then the tube was positioned in the anterior chamber or the sulcus. A donor sclera or a corneal lenticule was fashioned from banked tissue and secured with interrupted 8-0 vicryl sutures over the exposed portion of the tube.</i_keyword>
      <i_keyword>After informing the patients about the procedure, and signing a consent form, the patients were randomly divided in two groups to receive intra-operative MMC or a Placebo. The surgical procedure consisted of a 1-stage Ahmed Glaucoma Valve implantation using a standardized surgical technique for all patients. After administration of topical anesthesia (in both groups), a fornix or limbal based cojunctival flap was applied in the superotemporal quadrant. For the intervention group, a cotton applicator soaked in a balanced salt solution (BSS) was placed on the Episclera, under the conjunctiva and Tenon’s capsule for a contact time of 2 minutes ,at the site where the implant plate was to be placed, followed by irrigation with 30 ml of BSS. Then the tube was positioned in the anterior chamber or the sulcus. A donor sclera or a corneal lenticule was fashioned from banked tissue and secured with interrupted 8-0 vicryl sutures over the exposed portion of the tube.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intra oclar pressure. Timepoint: before intervention and one day and one week and one month and 3 months and 6 months and 12 months after intervention. Method of measurement: goldmann tonometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Tube-corneal contact. Timepoint: one day and one week and one month and 3 months and 6 moths and 12 months after intervention. Method of measurement: slit lamp exam.</sec_outcome>
      <sec_outcome>The number of drugs used to control intra ocular pressure. Timepoint: one day and one week and one month and 3 months and 6 moths and 12 months after intervention. Method of measurement: history.</sec_outcome>
      <sec_outcome>Hyphema. Timepoint: one day and one week and one month and 3 months after intervention. Method of measurement: slit lamp exam.</sec_outcome>
      <sec_outcome>Retraction of tube from anterior chamber. Timepoint: one day and one week and one month and 3 months and 6 moths and 12 months after intervention. Method of measurement: slit lamp exam.</sec_outcome>
      <sec_outcome>Tube/implant exposure. Timepoint: one day and one week and one month and 3 months and 6 moths and 12 months after intervention. Method of measurement: slit lamp exam.</sec_outcome>
      <sec_outcome>Flat chamber/transient hypotony. Timepoint: one day and one week  after intervention. Method of measurement: goldmann tonometer.</sec_outcome>
      <sec_outcome>Choroidal effusion. Timepoint: one day and one week and one month and 3 months and 6 moths and 12 months after intervention. Method of measurement: ocular ultrasonography.</sec_outcome>
      <sec_outcome>Blocked tube. Timepoint: one day and one week and one month and 3 months and 6 moths and 12 months after intervention. Method of measurement: slit lamp exam.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Farabi Eye Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-06-22</approval_date>
        <contact_name>Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran University of Medical Sciences, Keshavarz Blvd, Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
